Novavax and SK Group’s vaccine business subsidiary, SK Bioscience, have expanded collaboration and license agreement for manufacturing and commercialisation of the former’s Covid-19 vaccine, NVX-CoV2373, for sale to the Korean government.

NVX-CoV2373 is a protein-based vaccine candidate engineered from the genetic sequence of SARS-CoV-2, adjuvanted with Novavax’s Matrix-M.

With the agreement expansion, SK Bioscience will also increase production capacity.

The latest development is in addition to an already existing manufacturing arrangement between the companies for developing and supplying the protein antigen component of NVX-CoV2373 to be supplied to global markets such as the COVAX Facility.

This agreement calls for technology transfer linked to Novavax’s protein antigen manufacturing, Matrix M adjuvant supply and extending support to SK Bioscience to obtain regulatory approval.

Parallelly, SK Bioscience finalised an advance purchase agreement with the Korean government to supply 40 million doses of the vaccine starting this year.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Novavax president and CEO Stanley Erck said: “SK Bioscience shares our sense of urgency to deliver a safe and effective Covid-19 vaccine to protect the global population, including the people of South Korea.

“We are proud to expand our partnership, which is another great milestone for both companies toward increasing the supply of NVX-CoV2373.”

The company noted that the technology transfer and stepping up of production are progressing well under the previously announced collaboration.

Furthermore, NVX-CoV2373 is the first vaccine to show clinical efficacy against the original strain as well as the UK and South African variants of Covid-19.

SK Bioscience CEO Jaeyong Ahn said: “We are honoured to continue to manufacture Novavax’s innovative Covid-19 vaccine and provide a supply to the Korean Government through this agreement.

“We appreciate the collaboration of the Korean Government and Novavax to make possible this momentous step forward.”